Sacubitril/valsartan in PARADIGM-HF Reply

被引：0
|
作者：
Seferovic, Jelena P. [1 ]
Claggett, Brian [1 ]
Solomon, Scott D. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2017年 / 5卷 / 07期
关键词：
HEART-FAILURE; ENALAPRIL;
D O I：
10.1016/S2213-8587(17)30179-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：496 / 496
页数：1
相关论文
共 50 条
  • [1] Sacubitril/valsartan in PARADIGM-HF
    Flores, Dayana
    Sabti, Zaid
    Kozhuharov, Nikola
    Mueller, Christian
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (07): : 495 - 495
  • [2] The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
    Mogensen, Ulrik M.
    Kober, Lars
    Kristensen, Soren L.
    Jhund, Pardeep S.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Swedberg, Karl
    Zile, Michael R.
    Solomon, Scott D.
    Packer, Milton
    McMurray, John J. V.
    AMERICAN HEART JOURNAL, 2017, 188 : 35 - 41
  • [3] Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
    Curtain, James P.
    Adamson, Carly
    Docherty, Kieran F.
    Jhund, Pardeep S.
    Desai, Akshay S.
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Swedberg, Karl
    Zile, Michael R.
    Solomon, Scott D.
    Packer, Milton
    Mcmurray, John J. V.
    JACC-HEART FAILURE, 2023, 11 (07) : 749 - 759
  • [4] Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan
    Curtain, J.
    Adamson, C.
    Jhund, P. S.
    Desai, A. S.
    Lefkowitz, M. P.
    Rizkala, A. R.
    Rouleau, J. L.
    Swedberg, K.
    Zile, M. R.
    Solomon, S. D.
    Packer, M.
    McMurray, J. J. V.
    EUROPEAN HEART JOURNAL, 2022, 43 : 976 - 976
  • [5] SACUBITRIL/VALSARTAN ESTIMATED COST SAVINGS BASED ON PARADIGM-HF RESULTS
    Lacasa, C.
    Figueras, M.
    Obradors, M.
    VALUE IN HEALTH, 2016, 19 (07) : A656 - A656
  • [6] Sacubitril/Valsartan Neprilysin Inhibition 5 Years After PARADIGM-HF
    Docherty, Kieran F.
    Vaduganathan, Muthiah
    Solomon, Scott D.
    McMurray, John J., V
    JACC-HEART FAILURE, 2020, 8 (10) : 800 - 810
  • [7] EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF
    Simpson, Joanne
    Jhund, Pardeep
    Rouleau, Jean
    Swedberg, Karl
    Zile, Michael
    Lefkowitz, Martin
    Shi, Victor
    Solomon, Scott
    Packer, Milton
    McMurray, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 919 - 919
  • [8] Safety of sacubitril/valsartan in patients receiving statins in the PARADIGM-HF trial
    Streefkerk, H.
    Anand, D.
    Zhou, W.
    Balas, B.
    Schwende, H.
    Shi, V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 411 - 412
  • [9] Sacubitril/valsartan in PARADIGM-HF (vol 5, pg 495, 2017)
    Vodovar, N.
    Nougue, H.
    Launay, J-M
    Solal, A. C.
    Logeart, D.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (07): : E19 - E19
  • [10] Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation The PARADIGM-HF Trial
    Solomon, Scott D.
    Claggett, Brian
    Packer, Milton
    Desai, Akshay
    Zile, Michael R.
    Swedberg, Karl
    Rouleau, Jean
    Shi, Victor
    Lefkowitz, Martin
    McMurray, John J. V.
    JACC-HEART FAILURE, 2016, 4 (10) : 816 - 822
12345